ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics

ARCHIMED Acquires Majority Stake in Xpress Biologics

October 5, 2021

Biotechnology

ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.

ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)

November 3, 2021

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.

ARCHIMED Acquires Majority Stake in Cellese

April 9, 2024

Consumer Products

Global healthcare private equity firm ARCHIMED has acquired a majority stake in Cellese, the Irvine, California–based developer of growth factor- and exosome-based dermo-cosmetic products sold under the AnteAGE brand. ARCHIMED will support Cellese's commercialization and international expansion while founder Ian Sanderson and his family roll a meaningful portion of proceeds into a minority stake.

ARCHIMED Invests in PlasmidFactory

October 7, 2022

Biotechnology

Transatlantic healthcare private equity firm ARCHIMED (via its MED Platform II fund) has invested in PlasmidFactory, a Bielefeld, Germany-based contract manufacturer of plasmid and minicircle DNA used in gene and cell therapies. The founder and management will remain in place with a roll-over of a portion of proceeds; proceeds will fund rapid expansion including construction of a larger GMP-compliant production facility to meet growing demand.

ARCHIMED Acquires Stragen Pharma

June 24, 2021

Pharmaceuticals

ARCHIMED, through its MED Platform I fund, has acquired Stragen Pharma, a Switzerland-based developer, registrant and distributor of complex generics. The deal gives ARCHIMED majority ownership while Stragen's founder Jean‑Luc Tétard and management retain a significant minority stake; ARCHIMED plans to invest in product portfolio expansion and operational capabilities to accelerate growth in the generics market.

ARCHIMED Acquires Majority Stake in Germany's Zyto Group

January 12, 2021

Medical Devices

ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.